CureVac (NASDAQ:CVAC - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $3.62, but opened at $4.14. CureVac shares last traded at $4.07, with a volume of 388,877 shares.
Analysts Set New Price Targets
Separately, JMP Securities reaffirmed a "market outperform" rating and issued a $16.00 price objective on shares of CureVac in a report on Monday, September 16th.
Read Our Latest Report on CVAC
CureVac Stock Performance
The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company has a market cap of $994.03 million, a P/E ratio of 8.07, a P/E/G ratio of 0.24 and a beta of 2.50. The stock's fifty day moving average price is $2.93 and its two-hundred day moving average price is $3.11.
Institutional Trading of CureVac
Several institutional investors and hedge funds have recently modified their holdings of the business. Private Advisor Group LLC bought a new stake in shares of CureVac during the third quarter worth $30,000. International Assets Investment Management LLC acquired a new stake in shares of CureVac during the 3rd quarter valued at $35,000. Integrated Wealth Concepts LLC acquired a new stake in shares of CureVac during the 3rd quarter valued at $35,000. Bank of New York Mellon Corp bought a new stake in CureVac during the 2nd quarter worth $54,000. Finally, Barclays PLC acquired a new position in CureVac in the 3rd quarter worth about $67,000. 17.26% of the stock is currently owned by institutional investors.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
See Also
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
